A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2 Terminated
93 enrolled 27 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Phase 1/2 Terminated
58 enrolled 37 charts
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Phase 1/2 Terminated
13 enrolled 10 charts
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Terminated
9 enrolled 11 charts
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Phase 1/2 Terminated
109 enrolled 54 charts
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Phase 1/2 Terminated
21 enrolled 33 charts
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
Phase 1/2 Terminated
79 enrolled 18 charts
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1/2 Terminated
97 enrolled
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Phase 1/2 Terminated
43 enrolled 15 charts
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Phase 1/2 Terminated
7 enrolled 11 charts
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Phase 1/2 Terminated
31 enrolled 17 charts
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Phase 1/2 Terminated
51 enrolled 18 charts
PIVOT IO 020
Phase 1/2 Terminated
15 enrolled 14 charts
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Phase 1/2 Terminated
19 enrolled 15 charts
High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT
Phase 1/2 Terminated
5 enrolled
MT-3724NHL001
Phase 1/2 Terminated
38 enrolled 20 charts
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Phase 1/2 Terminated
17 enrolled 4 charts
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Phase 1/2 Terminated
58 enrolled
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
Phase 1/2 Terminated
31 enrolled 18 charts
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Phase 1/2 Terminated
5 enrolled 12 charts
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Phase 1/2 Terminated
28 enrolled
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase 1/2 Terminated
23 enrolled 12 charts
Phase II Study of TAK228 in Relapsed Lymphoma
Phase 1/2 Terminated
4 enrolled 9 charts
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Phase 1/2 Terminated
2 enrolled
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Phase 1/2 Terminated
8 enrolled 11 charts
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Phase 1/2 Terminated
2 enrolled 4 charts
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Phase 1/2 Terminated
2 enrolled 4 charts
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
Phase 1/2 Terminated
94 enrolled
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
32 enrolled 12 charts
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Phase 1/2 Terminated
1 enrolled 8 charts
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
Phase 1/2 Terminated
1 enrolled 3 charts
R²-DHAP
Phase 1/2 Terminated
34 enrolled
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
12 enrolled 14 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Phase 1/2 Terminated
31 enrolled 24 charts
HNJ-NKAES-2012
Phase 1/2 Terminated
7 enrolled
Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells
Phase 1/2 Terminated
3 enrolled
Stage I/II Nasal NK Cell Lymphoma
Phase 1/2 Terminated
1 enrolled 3 charts
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Phase 1/2 Terminated
5 enrolled
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Phase 1/2 Terminated
25 enrolled
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
Phase 1/2 Terminated
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Phase 1/2 Terminated
24 enrolled